pharmaceutical grade, PharmPure™ Pharmaceutical grade,PharmPure™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
The mRNA obtained by in vitro transcription has not undergone a series of intracellular modifications, does not have the Cap structure and PolyA tail, is easily degraded, easily activates the immune response, cannot bind to the ribosome initiation protein, and cannot initiate protein translation. Therefore, in the industrialized mRNA production, It is necessary to use vaccinia virus capping enzyme to cap the IVT mRNA to obtain the Cap0 structure at the 5'end of the mRNA, and further use 2'-O-methyltransferase to convert Cap0 to Cap1. The cap structure introduced by enzymatic capping is completely consistent with the natural cap structure in eukaryotes, which fundamentally reduces the immunogenicity of exogenous mRNA while protecting it from degradation, improving translation efficiency, and increasing intracellular protein production. Enzymatic capping can achieve a maximum capping efficiency of 100%, while capping by chemically synthesized cap analog structures has relatively low capping efficiency, and the structure of cap analogs is different from the natural cap structure.
The vaccinia virus capping enzyme adds the 7-methylguanosine cap structure (m7Gppp, Cap0) to the 5´ end of the RNA. In eukaryotes, this structure is closely related to the stability, transport and translation of mRNA. Enzymatic reaction to cap RNA is a simple and effective method, which can significantly improve the stability and translation ability of RNA used for in vitro transcription, transfection and microinjection. This enzyme is composed of two subunits (D1 and D12) (Figure 1a). The D1 subunit performs the functions of RNA triphosphatase and guanosine transferase, and the D12 subunit performs the functions of guanine methyltransferase. It is necessary to add a complete Cap0 structure m7Gppp5´N (Figure 1b).
This product can be used for the capping reaction of RNA produced by T7 RNA Polymerase and GMP Grade (GMP-E121, Novoprotein) reactions. The capping reaction is completed within one hour, with an efficiency close to 100% and ensuring the correct direction.
Recombinant vaccinia virus capping enzyme is expressed by large-scale fermentation in Escherichia coli. It is produced with medicinal-specific raw materials and strictly controlled host protein residues and nucleic acid residues. Product production and quality management procedures comply with GMP standards to ensure the production process and all raw materials Traceable.
Figure 1. The structure and mechanism of vaccinia virus capping. a. Co-crystal structure of vaccinia virus capping enzyme, GTP (red) and SAH (rose red) (PDB 4CKB). The enzyme consists of two subunits, D1 and D12, and has the functions of RNA triphosphatase (blue), guanosine transferase (orange) and guanine methyltransferase (beige). This figure is quoted from Ramanathan, A., Robb, GB, & Chan, SH (2016). mRNA capping: biological functions and applications. Nucleic Acids Res 44(16), 7511–7526. b. The cap structure of mRNA consists of a 7-Methylguanosine is composed of a 5'-5' triphosphate bridge connected to the 5'nucleoside of the mRNA chain. The Cap-0 structure is formed by the sequential reaction of three adjacent RNA strands. The further formation of cap-1 structure requires the participation of 2-O methyltransferase. This modification can reduce the cellular innate immune response caused by RNA in the body. This figure is quoted from Decroly, E., Ferron, F., Lescar, J. et al. (2012). Conventional and unconventional mechanisms for capping viral mRNA. Nat Rev Microbiol 10, 51–65.
Quality requirements
|
Follow the following specifications for production
1. ISO 9001:2015, certified facility.
2. "GMP Appendix-Cell Therapy Products" State Drug Administration.
3. "General Introduction to Human Gene Therapy-Chinese Pharmacopoeia 2020" National Pharmacopoeia Commission.
4. USP Chapter <1043>, Ancillary Materials for Cell, Gene, and Tissue-Engineered Products are used as excipients in cell therapy, gene therapy and tissue engineering products.
5. USP Chapter <92>, Growth Factors and Cytokines Used in Cell Therapy Manufacturing Cytokines and growth factors used in the production of cell therapy products.
6. Ph. Eur. General Chapter 5.2.12, Raw Materials of Biological Origin for the Production of Cell-based and Gene Therapy Medicinal Products.
Product Usage
Capping of mRNA before translation in vivo or in vitro and labeling of 5'end of mRNA.
Applications
The intact mRNA expresses GFP protein in the cell, the capping enzyme is compared with the cap analog
Precautions
1. The RNA used for the capping reaction should be purified and dissolved in nuclease-free water before use. The solution must not contain EDTA and salt.
2. When configuring the reaction system, 0.5 µl of RNase inhibitor (GMP-E125, Novoprotein) can be added, and an equal volume of RNase-free Water can be removed at the same time.
3. Heating the RNA before reacting with the capping enzyme can eliminate the 5´ secondary structure of the transcription product. If the structure of the 5´ end of the transcription product is complex, the heating time can be extended to 10 minutes.
4. SAM is unstable at pH 7-8, 37°C and needs to be freshly configured before the reaction starts. The amount of SAM can be calculated in advance, and the aliquoted 32 mM stock solution can be diluted to 2 mM working solution before the reaction starts. To avoid degradation of SAM, this working solution needs to be stored on ice.
5. If the 5´ end of the transcription product is known to have a complex structure, the reaction time can be extended to 60 minutes to increase the capping efficiency.
6. When labeling the 5´ end, the GTP stock solution should be diluted to 1–3 times the mRNA concentration.
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 I2202985 | Certificate of Analysis | Jun 11, 2026 | V406454 |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View PharmPure™ grade guide → View Pharmaceutical grade grade guide →
